Search Results

You are looking at 151 - 160 of 221 items for :

  • Refine by Access: All x
Clear All
Full access

Integrating Immune Therapies for the Treatment of Multiple Myeloma

Lekha Mikkilineni and Surbhi Sidana

Standard of Care Products CRS occurs due to immune activation, resulting in release of cytokines and immunologic proteins. 21 Common clinical manifestations of CRS include fever, tachycardia, hypotension, and hypoxia. 21 , 22 Severity of CRS depends

Full access

Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer

Pranav Murthy, Mazen S. Zenati, Samer S. AlMasri, Annissa DeSilva, Aatur D. Singhi, Alessandro Paniccia, Kenneth K. Lee, Richard L. Simmons, Nathan Bahary, Michael T. Lotze, and Amer H. Zureikat

Factors . Version 2.2023. Accessed June 1, 2023. To view the most recent version, visit https://www.nccn.org 5. Crawford J , Ozer H , Stoller R , Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by

Full access

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

Featured Updates to the NCCN Guidelines

Edward Schaeffer, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather Cheng, Anthony Victor D’Amico, Brian J. Davis, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Eric Mark Horwitz, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Rana McKay, Jesse McKenney, George Netto, David F. Penson, Julio M. Pow-Sang, Robert Reiter, Sylvia Richey, Mack Roach, III, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass

(range, 1.9 to ≥21.8 months). The most common adverse effects with pembrolizumab were fatigue, pruritus, diarrhea, anorexia, constipation, nausea, rash, fever, cough, dyspnea, and musculoskeletal pain. Pembrolizumab also may be associated with immune

Full access

Integration of Pediatric Hodgkin Lymphoma Treatment and Late Effects Guidelines: Seeing the Forest Beyond the Trees

Matthew J. Ehrhardt, Jamie E. Flerlage, Saro H. Armenian, Sharon M. Castellino, David C. Hodgson, and Melissa M. Hudson

/emesis, neuropathy, myelosuppression, and related fever and neutropenia) and the efficacy and convenience of outpatient biweekly delivery favor ABVD for adult oncology practices, the potential for late cardiotoxicity in children and adolescents due to higher

Full access

NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021

Featured Updates to the NCCN Guidelines

Efrat Dotan, Louise C. Walter, Ilene S. Browner, Katherine Clifton, Harvey Jay Cohen, Martine Extermann, Cary Gross, Sumati Gupta, Genevieve Hollis, Joleen Hubbard, Reshma Jagsi, Nancy L. Keating, Elizabeth Kessler, Thuy Koll, Beatriz Korc-Grodzicki, June M. McKoy, Sumi Misra, Dominic Moon, Tracey O’Connor, Cynthia Owusu, Ashley Rosko, Marcia Russell, Mina Sedrak, Fareeha Siddiqui, Amy Stella, Derek L. Stirewalt, Ishwaria M. Subbiah, William P. Tew, Grant R. Williams, Liz Hollinger, Giby V. George, and Hema Sundar

neutropenic fever and death. 35 , 36 Finally, a HCT-CI score ≥3 was found to be more predictive for a lower overall survival (OS) among patients aged ≥50 years who had undergone allogenic HCT. 37 For older adults with comorbidities, the panel recommends

Full access

New Options for the Management of Castration-Resistant Prostate Cancer: A Case Perspective

Dawn Goetz

regularly scheduled treatment, they must undergo an additional leukapheresis procedure. 21 , 22 The most common adverse events are chills, fatigue, fever, dyspnea, back pain, nausea, joint ache, and headache, most of which are mild and transient. 14 , 21

Full access

Molecular Classification Improves Therapeutic Options for Infants and Young Children With Medulloblastoma

Aditi Bagchi, Sandeep K. Dhanda, Paige Dunphy, Edgar Sioson, and Giles W. Robinson

, Survival and neurologic outcome of infants with medulloblastoma treated with surgery and MOPP chemotherapy. A preliminary report . Cancer 1987 ; 60 : 173 – 177 . 17. Boogerd W , van der Sande JJ , Moffie D . Acute fever and delayed

Full access

Abstracts From the NCCN 2023 Annual Conference

-lived memory CD8 T cells from individuals vaccinated for yellow fever. Furthermore, we show that CAR T cells were unable to mount an in vivo recall response after relapse of antigen-positive disease or recovery of endogenous B cells. Conclusions: These

Full access

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Lynn Wilson, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, and Hema Sundar

): peripheral blood lymphocyte counts less than 4 × 10 9 /L; absence of lymphadenopathy (ie, palpable nodes must be ≤1.5 cm in diameter); absence of splenomegaly or hepatomegaly; absence of constitutional symptoms (ie, weight loss, significant fatigue, fevers

Full access

Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology

Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Neel Gupta, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Oxana V. Makarova-Rusher, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Frank Palella, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Mary A. Dwyer, and Deborah A. Freedman-Cass

adverse interactions/lung toxicity with bleomycin in the NCCN Guidelines for HL, growth factors may be required in PLWH, especially if CD4+ T-cell counts are low and in the setting of prolonged severe neutropenia or neutropenic fever. Similarly, although